Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

Unintended events following immunization with MMR: a systematic review.

Jefferson T, Price D, Demicheli V, Bianco E; European Research Program for Improved Vaccine Safety Surveillance (EUSAFEVAC) Project.

Vaccine. 2003 Sep 8;21(25-26):3954-60. Review.

PMID:
12922131
[PubMed - indexed for MEDLINE]
2.

Vaccines for measles, mumps and rubella in children.

Demicheli V, Jefferson T, Rivetti A, Price D.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004407. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD004407.

PMID:
16235361
[PubMed - indexed for MEDLINE]
3.

Vaccines for measles, mumps and rubella in children.

Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD004407. doi: 10.1002/14651858.CD004407.pub3. Review.

PMID:
22336803
[PubMed - indexed for MEDLINE]
4.

Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project.

Black S, Shinefield H, Ray P, Lewis E, Chen R, Glasser J, Hadler S, Hardy J, Rhodes P, Swint E, Davis R, Thompson R, Mullooly J, Marcy M, Vadheim C, Ward J, Rastogi S, Wise R.

Pediatr Infect Dis J. 1997 May;16(5):500-3.

PMID:
9154545
[PubMed - indexed for MEDLINE]
5.

Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.

Wellington K, Goa KL.

Drugs. 2003;63(19):2107-26. Review.

PMID:
12962524
[PubMed - indexed for MEDLINE]
6.

An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines.

Dos Santos BA, Ranieri TS, Bercini M, Schermann MT, Famer S, Mohrdieck R, Maraskin T, Wagner MB.

Rev Panam Salud Publica. 2002 Oct;12(4):240-6.

PMID:
12431355
[PubMed - indexed for MEDLINE]
7.

Effect of gender on reporting of MMR adverse events in Saudi Arabia.

Khalil MK, Al-Mazrou YY, Al-Ghamdi YS, Tumsah S, Al-Jeffri M, Meshkhas A.

East Mediterr Health J. 2003 Jan-Mar;9(1-2):152-8.

PMID:
15562745
[PubMed - indexed for MEDLINE]
8.

Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.

Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G.

Pediatr Infect Dis J. 2005 Dec;24(12):1083-8.

PMID:
16371870
[PubMed - indexed for MEDLINE]
9.

Safety evaluation of MMR vaccine during a primary school campaign in Saudi Arabia.

Al-Mazrou Y, Tumsah S, Khalil M, Al-Jeffri M, Afzal MA, al-Ghamdy Y, Mishkhas A, Essa M.

J Trop Pediatr. 2002 Dec;48(6):354-8.

PMID:
12521278
[PubMed - indexed for MEDLINE]
10.

Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE.

Pediatrics. 2003 Oct;112(4):e325.

PMID:
14523220
[PubMed - indexed for MEDLINE]
11.

Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.

Asatryan A, Pool V, Chen RT, Kohl KS, Davis RL, Iskander JK; VAERS team.

Vaccine. 2008 Feb 26;26(9):1166-72. doi: 10.1016/j.vaccine.2007.12.049. Epub 2008 Jan 22. Review.

PMID:
18255204
[PubMed - indexed for MEDLINE]
12.

Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.

Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B.

Am J Epidemiol. 2007 Mar 15;165(6):704-9. Epub 2007 Jan 4.

PMID:
17204517
[PubMed - indexed for MEDLINE]
Free Article
13.

No evidence for links between autism, MMR and measles virus.

Chen W, Landau S, Sham P, Fombonne E.

Psychol Med. 2004 Apr;34(3):543-53.

PMID:
15259839
[PubMed - indexed for MEDLINE]
14.

Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany.

Schlipköter U, Mühlberger N, von Kries R, Weil J.

Infection. 2002 Dec;30(6):351-5.

PMID:
12478324
[PubMed - indexed for MEDLINE]
15.
16.

Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up.

Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H.

Pediatr Infect Dis J. 2000 Dec;19(12):1127-34.

PMID:
11144371
[PubMed - indexed for MEDLINE]
17.

Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management.

Mantadakis E, Farmaki E, Buchanan GR.

J Pediatr. 2010 Apr;156(4):623-8. doi: 10.1016/j.jpeds.2009.10.015. Epub 2010 Jan 25. Review.

PMID:
20097358
[PubMed - indexed for MEDLINE]
18.

Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra).

Dhillon S, Curran MP.

Paediatr Drugs. 2008;10(5):337-47. Review.

PMID:
18754700
[PubMed - indexed for MEDLINE]
19.

Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.

Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P.

Vaccine. 2009 Jan 14;27(3):446-53. doi: 10.1016/j.vaccine.2008.10.064. Epub 2008 Nov 11.

PMID:
19007835
[PubMed - indexed for MEDLINE]
20.

Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.

Goh P, Lim FS, Han HH, Willems P.

Infection. 2007 Oct;35(5):326-33. Epub 2007 Aug 20.

PMID:
17710370
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk